Jump to Main Content
- Surnar, Bapurao; Kolishetti, Nagesh; Basu, Uttara; Ahmad, Anis; Goka, Erik; Marples, Brian; Kolb, David; Lippman, Marc E.; Dhar, Shanta
- Biochemistry 2018 v.57 no.46 pp. 6500-6513
- DNA; DNA damage; adverse effects; antineoplastic activity; aspirin; cisplatin; drug therapy; in vitro studies; models; nausea; nephrotoxicity; neurotoxicity; patients; urinary bladder neoplasms
- ... Cisplatin is a major chemotherapeutic that continues to have a significant impact in the treatment of more than 50% of all cancers. Since its Food and Drug Administration approval in 1978 for the treatment of advanced ovarian and bladder cancer, this chemotherapeutic has made significant strides and its application has been extended to a large variety of other cancers. However, the vast majority o ...
- Buchanan, Mairin
K.; Needham, Chase N.; Neill, Nina E.; White, Maria C.; Kelly, Charles B.; Mastro-Kishton, Kelly; Chauvigne-Hines, Lacie M.; Goodwin, Tyler J.; McIver, Andrew L.; Bartolotti, Libero J.; Frampton, Arthur R.; Bourdelais, Andrea J.; Varadarajan, Sridhar
- Biochemistry 2017 v.56 no.2 pp. 421-440
- DNA; DNA damage; adverse effects; drug therapy; drugs; fluorescence; glucosamine; glucose transporters; humans; neoplasm cells; neoplasms; streptozotocin; toxicity
- ... DNA-alkylating drugs continue to remain an important weapon in the arsenal against cancers. However, they typically suffer from several shortcomings because of the indiscriminate DNA damage that they cause and their inability to specifically target cancer cells. We have developed a strategy for overcoming the deficiencies in current DNA-alkylating chemotherapy drugs by designing a site-specific DN ...